Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19
Journal of Paediatrics and Child Health · 2024
DOI: 10.1111/jpc.16569 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Paediatrics and Child Health, 2024. Verfasst von Tsuyoshi Jinda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Pediatrics, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aim
Remdesivir (RDV) causes liver enzyme elevation in adults; however, the frequency of this elevation in children and the associated risk factors are largely unknown. Therefore, we aimed to examine risk factors for liver enzyme elevation in hospitalised paediatric patients who received RDV.
Methods
This was a retrospective case–control study of all patients aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Pediatrics, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.
- Department of Pharmacy, Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyogo, Japan.
ORCID-Profile: Shinsuke Mizuno
Zitieren
APA
Jinda, T., Mizuno, S., Tatami, S., Kasai, M., & Ishida, T. (2024). Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.16569
Vancouver
Jinda T, Mizuno S, Tatami S, Kasai M, Ishida T. Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19. Journal of Paediatrics and Child Health. 2024. doi:10.1111/jpc.16569
BibTeX
@article{Jinda2024,
author = {Jinda, Tsuyoshi and Mizuno, Shinsuke and Tatami, Shunsuke and Kasai, Masashi and Ishida, Tatsuhiko},
title = {Risk factors for liver enzyme elevation with remdesivir use in the treatment of paediatric COVID‐19},
journal = {Journal of Paediatrics and Child Health},
year = {2024},
doi = {10.1111/jpc.16569}
}
EUVIMED